BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 16954163)

  • 1. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
    Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
    López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
    Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
    Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
    Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
    Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
    Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
    Merlo A; Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Pitiot AS; Balbín M; Astudillo A; Valdés N; Scola B; Del Toro R; Méndez-Ferrer S; Piruat JI; Suarez C; Chiara MD
    Oncotarget; 2017 Jan; 8(4):6700-6717. PubMed ID: 28036268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.
    Pandit R; Khadilkar K; Sarathi V; Kasaliwal R; Goroshi M; Khare S; Nair S; Raghavan V; Dalvi A; Hira P; Fernandes G; Sathe P; Rojekar A; Malhotra G; Bakshi G; Prakash G; Bhansali A; Walia R; Kamalanathan S; Sahoo J; Desai A; Bhagwat N; Mappa P; Rajput R; Chandrashekhar SR; Shivane V; Menon P; Lila A; Bandgar T; Shah N
    Eur J Endocrinol; 2016 Oct; 175(4):311-23. PubMed ID: 27539324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
    Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
    Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
    Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a signaling axis HIF-1α/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas.
    Merlo A; de Quiros SB; Secades P; Zambrano I; Balbín M; Astudillo A; Scola B; Arístegui M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2012 Nov; 97(11):E2194-200. PubMed ID: 22977270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma.
    Meyer-Rochow GY; Smith JM; Richardson AL; Marsh DJ; Sidhu SB; Robinson BG; Benn DE
    J Surg Res; 2009 Nov; 157(1):55-62. PubMed ID: 19215943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas.
    Dahia PL;
    Ann N Y Acad Sci; 2006 Aug; 1073():208-20. PubMed ID: 17102089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.
    Castelblanco E; Santacana M; Valls J; de Cubas A; Cascón A; Robledo M; Matias-Guiu X
    Endocr Pathol; 2013 Dec; 24(4):199-205. PubMed ID: 24096807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
    Srirangalingam U; Khoo B; Walker L; MacDonald F; Skelly RH; George E; Spooner D; Johnston LB; Monson JP; Grossman AB; Drake WM; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
    Endocr Relat Cancer; 2009 Jun; 16(2):515-25. PubMed ID: 19208735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
    Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
    Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients.
    Castellano M; Mori L; Giacchè M; Agliozzo E; Tosini R; Panarotto A; Cappelli C; Mulatero P; Cumetti D; Veglio F; Agabiti-Rosei E
    Ann N Y Acad Sci; 2006 Aug; 1073():156-65. PubMed ID: 17102082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.